{"schema_version":"secwatch.filing_event.v1","accession":"0001827090-25-000026","form_type":"8-K","ticker":"CERT","cik":"0001827090","company_name":"Certara, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.971613+00:00","generated_at":"2026-05-22T18:37:35.411978+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss","bullets":["Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).","Net income $4.7M vs net loss of $4.7M in Q1 2024; adjusted EBITDA $34.8M (+20%).","Reiterated full-year 2025 financial guidance.","CEO cites FDA roadmap for reducing animal testing as opportunity for biosimulation.","CFO notes strong commercial execution despite biopharma headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001827090-25-000026","json":"https://secwatch.observer/filing/0001827090-25-000026.json","markdown":"https://secwatch.observer/filing/0001827090-25-000026.md","text":"https://secwatch.observer/filing/0001827090-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827090/000182709025000026/0001827090-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827090/000182709025000026/certara-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T18:37:35.411978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}